timothy sykes logo
BIAF Stock Draws Traders As Nasdaq Compliance And Federal Deal Align Thumbnail
G Google News

BIAF Stock Draws Traders As Nasdaq Compliance And Federal Deal Align

TIM SYKES•UPDATED SEP. 17, 2026, 8:33 AM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

bioAffinity Technologies Inc. stocks have been trading up by 10.47 percent following highly positive coverage of its cancer diagnostics progress.

Key Takeaways

  • A new nationwide distribution deal puts CyPath Lung in front of VA and federal healthcare buyers through AvMEDICAL’s government-focused sales channels.
  • Management is positioning CyPath Lung for post-treatment surveillance of lung cancer survivors, not just early detection.
  • Upcoming H.C. Wainwright conference meetings spotlight BIAF’s commercial rollout and platform expansion to the Wall Street crowd.
  • Nasdaq compliance is restored for BIAF and its warrants, removing a delisting overhang and keeping the stock on a major exchange.

Candlestick Chart

Live Update At 08:32:35 EDT: On Thursday, September 17, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 10.47%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

BIAF is trading like a classic low-float biotech with real news and very real volatility. Over the recent stretch, bioAffinity Technologies Inc. ripped from the mid-$4s to an intraday high above $20, then bled back into the mid-$5s. For traders, that’s a textbook spike-and-fade pattern that still leaves BIAF well above its late-August base.

On the fundamentals, bioAffinity Technologies is early-stage and deeply unprofitable. Trailing revenue sits around $6.1M, but margins are heavily negative, with profit metrics showing steep losses as the company ramps commercialization of CyPath Lung. BIAF’s price-to-sales ratio near 1.27 is modest for a small-cap diagnostic name, signaling the market is not pricing in huge success yet.

More Breaking News

Cash flow is clearly under pressure. In the latest quarter ending 2026/06/30, BIAF burned more than $3.2M in operating cash flow and stayed afloat by issuing common stock. The balance sheet shows about $2.4M in cash and manageable debt, but the story here is dilution risk versus execution. For active traders, BIAF is a high-beta news vehicle, not a steady compounder.

Why Traders Are Watching BIAF Right Now

BIAF has three things that always get my community’s attention: a clear catalyst, a liquid Nasdaq listing, and a chart that proves it can move. The story starts with CyPath Lung, bioAffinity Technologies’ noninvasive lung cancer diagnostic. The company just locked in a nationwide federal distribution agreement with AvMEDICAL, plugging CyPath Lung directly into VA and other U.S. government healthcare systems.

That matters. Instead of BIAF slowly knocking on doors one hospital at a time, AvMEDICAL brings an established government-focused sales force and IDIQ contracting channels. Traders understand what that means: faster access to a large, stable, bureaucracy-driven buyer base. If ordering patterns ramp, revenue can become recurring and more predictable, which often re-rates a small-cap chart.

BIAF is also expanding CyPath Lung’s role. The test is moving beyond early detection into post-treatment surveillance of lung cancer survivors. That turns a one-off diagnostic into a tool that can be used repeatedly to monitor for recurrence or new primary tumors alongside imaging. For bioAffinity Technologies, that broadens the potential test volume from front-end screening to long-term survivorship care.

Layer on top the upcoming corporate update and one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference. That’s prime time for BIAF to sell its story to Wall Street while commercial momentum is building. Add in the September news that BIAF regained full Nasdaq compliance on both the common and warrants, and one big overhang — delisting risk — is off the table. The focus now shifts back to volume, revenue traction, and whether this ticker can repeat those parabolic moves traders love.

Conclusion

BIAF sits at the crossroads of story and numbers, which is where short-term trading opportunities often show up. On one hand, bioAffinity Technologies is still burning cash, posting quarterly net losses above $3.3M and relying on stock issuance to keep the lights on. On the other hand, the company now has a federal distribution partner in AvMEDICAL, growing clinical use cases for CyPath Lung, and a clean Nasdaq listing to support liquidity.

For traders, the play is rarely about believing or not believing the long-term vision. It’s about timing the waves as the market digests each new data point. A strong update from the H.C. Wainwright conference, signs of early order momentum from VA channels, or further validation of the surveillance use case can all reset sentiment around BIAF in a hurry.

At the same time, the ugly margins and ongoing cash burn mean any stall in progress can trigger sharp pullbacks. That’s why rule number one from this community always applies here. As Tim Sykes loves to say, “Cut losses quickly — you can always re-enter, but you can’t regrow a blown-up account.” That mindset lines up perfectly with his broader trading philosophy. As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. BIAF is a powerful teacher’s chart right now: respect the volatility, trade the catalysts, and never forget risk management. This analysis is for educational and research purposes only, but for disciplined traders, BIAF remains a name worth watching.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”